OncoVista Innovative Therapies Inc. (OVIT) Financials Nov 14, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for OncoVista Innovative Therapies Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 0 0 0 0 0
Cost of Goods Sold (COGS) incl. D&A 9,292 9,292 6,741 - 2,987
COGS excluding D&A 0 0 0 - 0
Depreciation & Amortization Expense 9,292 9,292 6,741 6,758 2,987
Depreciation 9,292 9,292 6,741 6,758 2,987
Amortization of Intangibles 0 0 0 - 0
Gross Income (9,292) (9,292) (6,741) - (2,987)
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 3.92M 2.39M 2.19M 1.97M 1.52M
Research & Development 1.48M 450,910 1.16M 1.1M 900,558
Other SG&A 2.44M 1.94M 1.04M 874,252 618,645
Other Operating Expense 0 0 0 0 0
Unusual Expense (568,512) (265,299) 21,429 (355,129) (72,468)
EBIT after Unusual Expense 568,512 265,299 (21,429) 355,129 72,468
Non Operating Income/Expense 28,655 (9,709) 10,024 883 0
Non-Operating Interest Income 0 0 7,023 3,368 261
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 669,294 147,012 24,073 6,847 152
Gross Interest Expense 669,294 147,012 24,073 6,847 152
Interest Capitalized 0 0 0 0 0
Pretax Income (4M) (2.29M) (2.23M) (1.63M) (1.45M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (4M) (2.29M) (2.23M) (1.63M) (1.45M)
Minority Interest Expense 0 0 0 0 0
Net Income (4M) (2.29M) (2.23M) (1.63M) (1.45M)
Extraordinaries & Discontinued Operations (782,969) 12.39M 204,438 0 0
Extra Items & Gain/Loss Sale Of Assets 0 12.67M 204,438 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations (782,969) (272,185) 0 0 0
Net Income After Extraordinaries (4.78M) 10.1M (2.03M) (1.63M) (1.45M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (4M) (2.29M) (2.23M) (1.63M) (1.45M)
EPS (Basic) (0.26) (0.13) (0.10) (0.08) (0.07)
Basic Shares Outstanding 18.42M 20.48M 21.31M 21.51M 21.63M
EPS (Diluted) (0.26) (0.13) (0.10) (0.08) (0.07)
Diluted Shares Outstanding 18.42M 20.48M 21.31M 21.51M 21.63M
EBITDA (3.92M) (2.39M) (2.19M) (1.97M) (1.52M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for OncoVista Innovative Therapies Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 0 0 0 0 0
Cost of Goods Sold (COGS) incl. D&A 9,292 9,292 6,741 - 2,987
COGS excluding D&A 0 0 0 - 0
Depreciation & Amortization Expense 9,292 9,292 6,741 6,758 2,987
Depreciation 9,292 9,292 6,741 6,758 2,987
Amortization of Intangibles 0 0 0 - 0
Gross Income (9,292) (9,292) (6,741) - (2,987)
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 3.92M 2.39M 2.19M 1.97M 1.52M
Research & Development 1.48M 450,910 1.16M 1.1M 900,558
Other SG&A 2.44M 1.94M 1.04M 874,252 618,645
Other Operating Expense 0 0 0 0 0
Unusual Expense (568,512) (265,299) 21,429 (355,129) (72,468)
EBIT after Unusual Expense 568,512 265,299 (21,429) 355,129 72,468
Non Operating Income/Expense 28,655 (9,709) 10,024 883 0
Non-Operating Interest Income 0 0 7,023 3,368 261
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 669,294 147,012 24,073 6,847 152
Gross Interest Expense 669,294 147,012 24,073 6,847 152
Interest Capitalized 0 0 0 0 0
Pretax Income (4M) (2.29M) (2.23M) (1.63M) (1.45M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (4M) (2.29M) (2.23M) (1.63M) (1.45M)
Minority Interest Expense 0 0 0 0 0
Net Income (4M) (2.29M) (2.23M) (1.63M) (1.45M)
Extraordinaries & Discontinued Operations (782,969) 12.39M 204,438 0 0
Extra Items & Gain/Loss Sale Of Assets 0 12.67M 204,438 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations (782,969) (272,185) 0 0 0
Net Income After Extraordinaries (4.78M) 10.1M (2.03M) (1.63M) (1.45M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (4M) (2.29M) (2.23M) (1.63M) (1.45M)
EPS (Basic) (0.26) (0.13) (0.10) (0.08) (0.07)
Basic Shares Outstanding 18.42M 20.48M 21.31M 21.51M 21.63M
EPS (Diluted) (0.26) (0.13) (0.10) (0.08) (0.07)
Diluted Shares Outstanding 18.42M 20.48M 21.31M 21.51M 21.63M
EBITDA (3.92M) (2.39M) (2.19M) (1.97M) (1.52M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
